Article
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
The New England journal of medicine - 28 Oct 2010
Paré Guillaume, Mehta Shamir R, Yusuf Salim, Anand Sonia S, Connolly Stuart J, Hirsh Jack, Simonsen Katy, Bhatt Deepak L, Fox Keith A A, Eikelboom John W
Abstract excerpt
BACKGROUND: It has been suggested that clopidogrel may be less effective in reducing the rate of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 alleles that are associated with reduced conversion of clopidogrel to its active metabolite. METHODS: We genotyped patients from two large, randomized trials that showed that clopidogrel, as compared with placebo, reduced the rate of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.